{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelodysplastic+Syndromes&page=14",
    "query": {
      "condition": "Myelodysplastic Syndromes",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 1797,
    "total_pages": 180,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelodysplastic+Syndromes&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelodysplastic+Syndromes&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T19:06:56.975Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02078609",
      "title": "A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "AML and High Risk MDS"
      ],
      "interventions": [
        {
          "name": "LGH447",
          "type": "DRUG"
        },
        {
          "name": "LGH447 + midostaurin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2014-03-20",
      "completion_date": "2019-04-18",
      "has_results": false,
      "last_update_posted_date": "2020-12-17",
      "last_synced_at": "2026-10-17T19:06:56.975Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02078609"
    },
    {
      "nct_id": "NCT02279654",
      "title": "Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 389,
      "start_date": "2014-12-17",
      "completion_date": "2022-03-29",
      "has_results": false,
      "last_update_posted_date": "2022-08-19",
      "last_synced_at": "2026-10-17T19:06:56.975Z",
      "location_count": 13,
      "location_summary": "Centre City, New Jersey • No City Provided, New Jersey",
      "locations": [
        {
          "city": "Centre City",
          "state": "New Jersey"
        },
        {
          "city": "Centre City",
          "state": "New Jersey"
        },
        {
          "city": "No City Provided",
          "state": "New Jersey"
        },
        {
          "city": "No City Provided",
          "state": "New Jersey"
        },
        {
          "city": "No City Provided",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02279654"
    },
    {
      "nct_id": "NCT04055844",
      "title": "Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myeloid and Monocytic Leukemia",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Donor Lymphocyte Infusion (DLI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2020-02-17",
      "completion_date": "2022-09-06",
      "has_results": true,
      "last_update_posted_date": "2023-11-07",
      "last_synced_at": "2026-10-17T19:06:56.975Z",
      "location_count": 3,
      "location_summary": "Minneapolis, Minnesota • St Louis, Missouri • Rochester, New York",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04055844"
    },
    {
      "nct_id": "NCT03173937",
      "title": "Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Severe Aplastic Anemia",
        "Hypo-Plastic MDS",
        "Myelodysplastic Syndrome (MDS)"
      ],
      "interventions": [
        {
          "name": "Omidubicel (former CordIn)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Miltenyi CliniMACS(R) CD34 Reagent System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "4 Years to 75 Years"
      },
      "enrollment_count": 37,
      "start_date": "2017-06-13",
      "completion_date": "2032-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-17T19:06:56.975Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03173937"
    },
    {
      "nct_id": "NCT00943592",
      "title": "Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Hematologic Malignancies",
        "Leukemia",
        "Preleukemia"
      ],
      "interventions": [
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Campath",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell Transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 82,
      "start_date": "2006-03",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2014-02-27",
      "last_synced_at": "2026-10-17T19:06:56.975Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00943592"
    },
    {
      "nct_id": "NCT01700751",
      "title": "Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia, Acute Myeloid",
        "Leukemia, Lymphoblastic,Acute",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "brentuximab vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 17,
      "start_date": "2013-02-25",
      "completion_date": "2016-11-21",
      "has_results": false,
      "last_update_posted_date": "2019-04-16",
      "last_synced_at": "2026-10-17T19:06:56.975Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01700751"
    },
    {
      "nct_id": "NCT01335165",
      "title": "Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Paroxysmal Nocturnal Hemoglobinuria (PNH)"
      ],
      "interventions": [
        {
          "name": "ALXN1102",
          "type": "DRUG"
        },
        {
          "name": "ALXN1103",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2011-04",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2014-05-22",
      "last_synced_at": "2026-10-17T19:06:56.975Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01335165"
    },
    {
      "nct_id": "NCT00251511",
      "title": "A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Arsenic Trioxide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veeda Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 60,
      "start_date": "2004-08",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2012-05-11",
      "last_synced_at": "2026-10-17T19:06:56.975Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00251511"
    },
    {
      "nct_id": "NCT05146739",
      "title": "Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia Post Cytotoxic Therapy",
        "Myelodysplastic Syndrome Post Cytotoxic Therapy",
        "Myeloid Leukemia Associated With Down Syndrome",
        "Recurrent Acute Myeloid Leukemia",
        "Recurrent Mixed Phenotype Acute Leukemia",
        "Recurrent Myelodysplastic Syndrome",
        "Refractory Acute Myeloid Leukemia",
        "Refractory Mixed Phenotype Acute Leukemia",
        "Refractory Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Triple Intrathecal Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Uproleselan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 8,
      "start_date": "2023-10-10",
      "completion_date": "2027-05-09",
      "has_results": true,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-10-17T19:06:56.975Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05146739"
    },
    {
      "nct_id": "NCT00005622",
      "title": "Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Multiple Myeloma and Malignant Plasma Cell Neoplasms",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "TBI",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "15 Years to 50 Years"
      },
      "enrollment_count": 72,
      "start_date": "1996-05",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2012-10-25",
      "last_synced_at": "2026-10-17T19:06:56.975Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005622"
    }
  ]
}